Vitamin D and Reduced Disease Recurrence

Doses used in studies

IU/day: 2,000 (median 2,000, IQR 2,000–2,000) — 1 study

Time to effect

Median: 36.5 months · IQR 36.5 months–36.5 months · Range 36.5 months–36.5 months — Reported in 1 of 1 study

1 of 1 paper

Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial.

2021-06-04
RCT
Nutrients 13(6)
- Harriet Johansson
- Giuseppe Spadola
- Giulio Tosti
- Mario Mandalà
- Alessandro M Minisini
- Paola Queirolo
- Valentina Aristarco
- Federica Baldini
- Emilia Cocorocchio
- Elena Albertazzi
- Leonardo Zichichi
- Saverio Cinieri
- Costantino Jemos
- Giovanni Mazzarol
- Patrizia Gnagnarella
- Debora Macis
- Ines Tedeschi
- Emanuela Omodeo Salè
- Luigia Stefania Stucci
- Bernardo Bonanni
- Alessandro Testori
- Elisabetta Pennacchioli
- Pier Francesco Ferrucci
- Sara Gandini
- On Behalf Of The Italian Melanoma Intergroup Imi

PubMed: 34199802
DOI: 10.3390/nu13061931

1 Insight on

Reduced Disease Recurrence

High evidence
Rigorous Journal
Clinical

After 12 months, subjects with low 25OHD levels and Breslow score ≥3 mm had shorter disease-free survival (p = 0.02) compared to those with Breslow score <3 mm and/or high levels of 25OHD. Adjusting for age and treatment arm, the hazard ratio for relapse was 4.81 (95% CI: 1.44-16.09, p = 0.011).

Effect: Beneficial
Effect size: Large
Significant: Yes
Dose: 100,000 IU every 50 days